SAN DIEGO, May 17, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held June 4 – 8, 2010 at the McCormick Place Convention Center in Chicago. Illinois. Apoptone is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to induce cell death (apoptosis) in animal models of prostate and breast cancers.
Presenting the poster is the lead investigator of the study, R. Bruce Montgomery, M.D., Associate Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine. The study is being conducted with participating member sites of the Prostate Cancer Clinical Trial Consortium (PCCTC). Earlier data from this study were presented in March at the ASCO Genitourinary Cancers Symposium.
Title: HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant
prostate cancer (CRPC): Results of phase I/II clinical trial.
Track: Genitourinary Cancer
Poster #: 4674 Location: S Hall A2
Presentation Time: Monday, June 7, 1:00 PM - 5:00 PM
About Harbor BioSciences, Inc.
Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone, in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone and Triolex represent the lead candidates from Harbor BioSciences' small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones. For more information on Harbor BioSciences please visit www.harborbiosciences.com.